Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") announced that it was publicizing the full technical (unedited) report in Japanese, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease (NIID, formerly Japan's National Institute of Health) and the certified English translation. The full report, now available on the Company's website, summarizes the results of a three (3) year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine. The report, entitled "Research on Clinical Applications of Influenza Vaccines Formulated for Nasal Mucosal Delivery" was originally filed with Japan's Ministry of Health, Labor and Welfare (MHLW), which fully funded this work in non-human primates. All reports under grants from MHLW are submitted first to MHLW and then forwarded to the National Diet Library to be made available for public review. In response to ongoing inquiries, the Company is publishing the full report. The Company invites continuing dialogue with clinical researchers in influenza as well as epidemiologists monitoring global incidence rates of seasonal and pandemic influenza.
Dr. William Carter, Chairman and CEO of Hemispherx, reiterated that "Dr. Hasegawa's work over the last three years brings into sharp focus Ampligen®'s (an experimental therapeutic) dose-response role in enhancing and extending both the IgA and IgG immune responses and to this vaccine against a pandemic H5N1 virus. The Lancet publication and WHO surveillance data (please see Hemispherx's release of July 12, 2010) highlight the continuing global threat of pandemic influenza and the need to develop novel more effective approaches to disease control."
New nasal vaccine could help stop the spread of whooping cough